Lundbeck announces the resignation of Marie-Laure Pochon, Executive Vice President, Commercial Operations
H. Lundbeck A/S (Lundbeck) today announced that Marie-Laure Pochon, Executive Vice President, Commercial Operations, has decided to resign from her position at Lundbeck for family and private reasons.
”I have had a fantastic journey with Lundbeck and feel that the company now has a strong commercial platform with many product launches in the near-term future. However, for family and private reasons, I have made the decision to resign,” says Marie-Laure Pochon.
“I respect Marie-Laure’s decision and would like to thank her for her dedication and contribution to Lundbeck during the five years she has been with the company,” says Ulf Wiinberg, President & CEO of Lundbeck and continues: “We will continue the implementation of our commercial strategy to diversify our product portfolio and expand geographically with our strong and very capable commercial leadership team."
Senior Vice President Ole Chrintz, who is currently responsible for Lundbeck’s international markets, will add Lundbeck’s commercial operations in Europe to his area. He is already a member of Lundbeck’s Corporate Management Group (CMG) and will report to CEO Ulf Wiinberg. Vice President Andreas Eggert, Global Product Strategy & Portfolio Development and member of the CMG and Staffan Schuberg, President, Lundbeck US, will also report directly to Ulf Wiinberg.
Lundbeck’s Executive Management now consists of
- Ulf Wiinberg, President & CEO
- Anders Götzsche, Executive Vice President, CFO
- Anders Gersel Pedersen, Executive Vice President, R&D
Financial guidance
The content of this release will have no influence on the Lundbeck Group's financial guidance for 2012 which was provided on 8 February 2012 in connection with the release of the financial results for 2011.
Lundbeck contacts
| Investors: | Media: |
| Palle Holm Olesen | Mads Kronborg |
| Chief Specialist, Head of Investor Relations | Media Relations Manager |
| palo@lundbeck.com | mavk@lundbeck.com |
| +45 36 43 24 26 | +45 36 43 28 51 |
| Magnus Thorstholm Jensen | Simon Mehl Augustesen |
| Investor Relations Officer | International Media Specialist |
| matj@lundbeck.com | smeh@lundbeck.com |
| +45 36 43 38 16 | +45 36 43 49 80 |
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world’s leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.1 billion or USD 3.0 billion). For more information, please visit www.lundbeck.com.